Revumenib (Revuforj) is hard to find because it's a specialty oncology drug with limited distribution. Learn why and what you can do about it in 2026.
If your doctor recently prescribed Revumenib (brand name Revuforj) for acute leukemia and you're having trouble filling your prescription, you're not imagining things. This first-in-class menin inhibitor is one of the hardest medications to find in 2026 — and there are real reasons for that.
Revumenib is not the kind of drug you can pick up at your local pharmacy. It's a specialty oncology medication with a very specific distribution pathway, and that can make the process of actually getting it feel overwhelming — especially when you're already dealing with a serious diagnosis.
In this article, we'll explain exactly what Revumenib is, why it's so difficult to find, and what steps you can take to get your prescription filled.
Revumenib, sold under the brand name Revuforj, is an oral medication made by Syndax Pharmaceuticals. It was approved by the FDA in November 2024 as the first and only menin inhibitor for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adults and children aged 1 year and older.
In October 2025, the FDA expanded its approval to also cover relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation in patients who have no satisfactory alternative treatment options.
Revumenib works by blocking the interaction between two proteins — menin and KMT2A (also called MLL). In certain leukemias, this interaction drives cancer cell growth. By disrupting it, Revumenib helps stop leukemia cells from multiplying and encourages them to mature normally.
The medication comes as tablets in 25 mg, 110 mg, and 160 mg strengths. Most adult patients take 270 mg twice daily, or 160 mg twice daily if they are also taking a strong CYP3A4 inhibitor like Posaconazole or Voriconazole.
For more details about how this drug works, see our guide on how Revumenib works.
There are several reasons why Revumenib is difficult to find. Understanding them can help you navigate the process more effectively.
Revumenib is not stocked at regular retail pharmacies like CVS, Walgreens, or Walmart. Because it's a high-cost specialty oncology drug — with a wholesale acquisition cost of approximately $39,500 per month — it is distributed exclusively through specialty pharmacy channels.
Specialty pharmacies are equipped to handle complex medications that require special storage, patient monitoring, or clinical support. But this also means you can't just walk into your neighborhood pharmacy and pick up your prescription.
Revumenib received FDA orphan drug designation because it treats a rare form of leukemia. The number of patients who need this drug is relatively small compared to medications for common conditions like high blood pressure or diabetes. This means fewer pharmacies carry it, and distribution networks are more limited.
Most insurance plans require prior authorization before they will cover Revumenib. Your doctor will need to confirm through FDA-authorized testing that your leukemia has a KMT2A translocation or NPM1 mutation. This process can take days or even weeks, which adds to the delay in getting your medication.
Revumenib was only approved in late 2024, and its indication was expanded in late 2025. As a newer drug, the supply chain and distribution pathways are still maturing. Some specialty pharmacies may not have it in stock or may need to order it specifically for you.
For an in-depth look at supply issues, read our Revumenib shortage update for 2026.
Even though finding Revumenib is challenging, there are concrete steps you can take to improve your chances of filling your prescription quickly.
Syndax Pharmaceuticals operates a patient support program called SyndAccess. This program can help you with:
You can reach SyndAccess at 1-888-567-SYND (7963), Monday through Friday, 8 AM to 8 PM ET, or visit syndaccess.com.
Hematology and oncology practices deal with specialty medications regularly. Your doctor's office likely has staff who specialize in navigating prior authorizations and specialty pharmacy orders. Don't hesitate to ask them for help — they've been through this process before.
Tools like Medfinder can help you check which pharmacies have Revumenib in stock in your area. This can save you hours of calling around.
For more tips, check out our guide on how to find Revumenib in stock near you.
At roughly $474,000 per year, the cost of Revumenib can be a major barrier even with insurance. If cost is a concern, explore our detailed breakdown of how to save money on Revumenib in 2026.
Revumenib is a groundbreaking treatment for patients with relapsed or refractory acute leukemia — but getting access to it is not simple. Between specialty pharmacy requirements, prior authorization hurdles, and the drug's limited distribution, finding Revumenib takes patience and persistence.
The good news is that resources like SyndAccess, your oncology team, and tools like Medfinder can help you navigate the process. If you're struggling, don't give up — and don't try to do it alone.
For more information about this medication, read our complete overview: What is Revumenib? Uses, dosage, and what you need to know.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
